drugset / Trial / NCT05022108

Alpha-Bisabolol Gel With Antihistamine Action

NCT05022108 ↗

Phase 1 Completed 20 enrolled Universidade do Vale do Sapucai
NaSingle-groupOpen-labelTreatment

Summary

It will be developed and evaluated the antihistamine potential of a gel containing alpha-bisabolol. Method: Interventional and cross-sectional study, with convenience sampling, conducted with 20 volunteers. The forearm will be sensitized at four points (A, B, C and D). Point A: positive control will be sensitized with a drop of histamine at a concentration of 10 mg / Ml. Point B: histamine will apply and immediately after, the alpha bisabolol gel with a concentration of 0.5%. Point C: histamine and gel with 2.5% alpha-bisabolol will apply. Point D will be sensitized with a drop of histamine and 5.0% alpha-bisabolol gel. The test reading at each point will occur 15 minutes after the procedure. For the analysis of the results, the T Test will be applied.

Timeline

Start
2020-04-01
Primary completion
2020-08-01
Completion
2020-12-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Alpha bisabolol Small molecule 0.5 % Topical
Subject Alpha bisabolol Small molecule 2.5 % Topical
Subject Alpha bisabolol Small molecule 5 % Topical

Indications

No indication recorded.